Last reviewed · How we verify

Placebo of Perindopril (P1)

Hospices Civils de Lyon · FDA-approved active Small molecule

Placebo of Perindopril (P1) is a Small molecule drug developed by Hospices Civils de Lyon. It is currently FDA-approved.

This is a placebo formulation with no active pharmacological mechanism.

At a glance

Generic namePlacebo of Perindopril (P1)
SponsorHospices Civils de Lyon
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. It is used as a control in clinical trials to compare against the active drug (perindopril in this case) and to assess the placebo response independent of the drug's mechanism.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of Perindopril (P1)

What is Placebo of Perindopril (P1)?

Placebo of Perindopril (P1) is a Small molecule drug developed by Hospices Civils de Lyon.

How does Placebo of Perindopril (P1) work?

This is a placebo formulation with no active pharmacological mechanism.

Who makes Placebo of Perindopril (P1)?

Placebo of Perindopril (P1) is developed and marketed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).

What development phase is Placebo of Perindopril (P1) in?

Placebo of Perindopril (P1) is FDA-approved (marketed).

Related